Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DMX 101

Drug Profile

DMX 101

Alternative Names: APO-200; DMX-101; EDI200; ER-004; Fc EDA1; Fc:EDA-A1 fusion protein; Human immunoglobulin G1 constant region - human ectodysplasin-A1 receptor-binding domain fusion protein; Hypohidrotic ectodermal dysplasia therapy - Edimer; Recombinant ectodysplasin A1; Recombinant EDA1; XLHED therapy - Edimer

Latest Information Update: 08 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Apoxis
  • Developer Dermelix Biotherapeutics; Edimer Pharmaceuticals; EspeRare Foundation; Pierre Fabre
  • Class Immunoglobulin Fc fragments; Immunoglobulin fusion proteins; Recombinant fusion proteins; Tumour necrosis factors
  • Mechanism of Action Protein replacements; Tumour necrosis factor receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ectodermal dysplasia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ectodermal dysplasia

Most Recent Events

  • 28 May 2023 No recent reports of development identified for preclinical development in Ectodermal dysplasia in USA (Intra-amniotic, Injection)
  • 28 Aug 2022 No recent reports of development identified for clinical-Phase-Unknown development in Ectodermal dysplasia in Switzerland (Intra-amniotic, Injection)
  • 25 Oct 2021 Phase-II clinical trials in Ectodermal dysplasia in Italy (Intra-amniotic) (NCT04980638), Italy (Intra-amniotic) (NCT04980638), France (Intra-amniotic) (NCT04980638) (EudraCT2021-002532-23)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top